ALSO READLupin: Price erosion still a key concern Lupin eyes share of $48 mn market with anti-infection capsule launch in US Lupin receives USFDA nod to market Tamiflu capsules to treat influenza Lupin gets USFDA warning for Goa & Pithampur plants, stock tanks 15% Lupin gets USFDA approval for generic vibra-tabs tablet
The Mumbai-based firm has introduced its legacy product 'Softovac' across the country as an OTC medicine.
"It was imperative for us to enter the OTC segment as the vertical has been steadily growing over the years in the country. Over a horizon of five years we are looking at a turnover of Rs 3 billion (Rs 300 crore) from the business," Lupin Head OTC Business Anil Kaushal told PTI.
For over 30 years, Softovac has been a product of choice for many patients who suffer from constipation and considering the widespread prevalence of this condition, the shift from prescription to OTC has made it more accessible to those who need it the most, he added.
Lupin, one of the top five pharma companies in the country, plans to launch a variety of products across various categories like vitamins/minerals and lifestyle OTC products going ahead, Kaushal said.
According to industry sources, the Indian consumer healthcare business is pegged at around USD 2.7 billion (over Rs 18,800 crore) and is expected to touch USD 6 billion mark (over Rs 40,000 crore) by around 2026.
Lupin Managing Director Nilesh Gupta said: "The OTC segment is one of the fastest growing segments in the Indian pharmaceutical market. This, combined with our capabilities and expertise in this space, makes it a lucrative business opportunity for Lupin."
The company's long-term strategy is to have a portfolio of new products as well as offerings like Softovac, all of it aimed at addressing the unmet needs of patients, he added.
Lupin shares were trading 0.13 per cent down at Rs 917.95 on BSE.